“国产ADC一哥”荣昌生物也曾被资本市场寄予无限厚望,巅峰市值一度站在400亿元高位,如今仅剩下83亿元的估值,并且在去年还传出现金流紧张等“绯闻”。但真的是验证了“厄运专找苦命人”,本就被资金短缺等困境折磨的荣昌生物,似乎再添“一难”:公司首席战略官何如意博士在2025年的第一周,提交了自己的辞呈。这意味着,荣昌此前仰仗的3大骨干技术人才,仅剩下公司CEO房健民博士一人。01为何离职据悉,何如意...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.